January 14, 2020
Visicell Medical Team
We saw lots of action in the biopharma merger and acquisition (M&A) space in 2019, headlined by Bristol-Myers Squibb acquiring Celgen...
November 24, 2019
We proudly introduce the newest addition to the Visicell family, the Visicell Board of Advisors:
George Smith, PhD, MBA
June 11, 2019
Almost 10 years after this was first observed, a second patient has now gone into remission for HIV after receiving a stem cell trans...
It is clear that there is a need for safety regulation in the cell therapy market. This article discusses the need for increased regu...
April 15, 2019
According to a Nature article, the Japanese health ministry is expected to soon decide on a reprogrammed stem cell therapy for damage...
The FDA has stepped up its enforcement on unapproved therapies in many stem cell clinics across the United States. With false promise...
A partnership between Dan Kauffman, MD, PhD, at the Sanford Consortium of Regenerative Medicine, local biotech Fate Pharmaceuticals,...
March 6, 2019
Visicell visited California Institute of Regenerative medicine (CIRM) and presented their recent development on non-invasive cell tra...
February 28, 2019
Visicell had recently joined HESI CT-TRACS, a global committee with multiple stakeholders ranging from academic institutions, biotech...
November 30, 2018
Visicell is proud recipient of a grant from StartR Inclusion (formerly known as mystartupXX), and is grateful for StartR's continued...
Our Recent Posts
A record year for biopharma M&A in 2019
Kicking off the Visicell Advisory Board with a bang!
Stem-cell transplant in the clinic leading to HIV remission